North America Acute Myeloid Leukemia Diagnostics Market to 2032
Overview
The North America Acute Myeloid Leukemia Diagnostics Market is expected to reach a 2.98 USD Billion by 2032 and is projected to grow at a CAGR of 16.70% from 2025 to 2032.
Revenue, 2024 (USD Billion)
1.26
Forecast, 2032 (USD Billion)
2.98
CAGR, 2024 - 2032
16.70%
Report Coverage
North America
North America Acute Myeloid Leukemia Diagnostics Market 2018-2032 USD Billion
North America Acute Myeloid Leukemia Diagnostics Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 1.26 USD Billion
- Projected Market Size (2032): 2.98 USD Billion
- CAGR (2025-2032): 16.70%
Key Findings of North America Acute Myeloid Leukemia Diagnostics Market
- The North America Acute Myeloid Leukemia Diagnostics Market was valued at 1.26 USD Billion in 2024.
- The North America Acute Myeloid Leukemia Diagnostics Market is likely to grow at a CAGR of 16.70% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment 65 and Above in Age Group Segment accounted for the largest share of the market with a revenue of 0.96 USD Billion
- The fastest growing segment Myeloblastic (M0) in Cancer Segment grew Fastest with a CAGR of 23.49% during the forecast period from 2024 to 2032.
North America Acute Myeloid Leukemia Diagnostics Market Scope
North America Acute Myeloid Leukemia Diagnostics Market Segmentation & Scope
Product
- Consumables & Accessories
- Instruments
Test
- Others
- Immunophenotyping
- Biomarker Test
- Genetic Tests
- Bone Marrow Tests
- Imaging Test
- Blood Test
Gender
- Female
- Male
End User
- Others
- Cancer Research Institutes
- Diagnostic Imaging Centers
- Independent Diagnostic Laboratories
- Associated Labs
- Hospitals
Distribution Channel
- Retail Sales
- Direct Tender
Age Group
- 21-29
- Below 21
- 30-65
- 65 and Above
Cancer
- Megakaryocytic (M7)
- Erythroleukemia (M6)
- Monocytic (M5)
- Myelomonocytic (M4)
- Promyelocytic (M3)
- Myeloblastic (M2)
- Myeloblastic (M1)
- Myeloblastic (M0)
North America Acute Myeloid Leukemia Diagnostics Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 1.26 USD Billion |
| Market Value in 2032 | 2.98 USD Billion |
| CAGR (2025-2032) | 16.70% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Product,Test,Gender,End User,Distribution Channel,Age Group,Cancer |
Regional Insights:
-
Leading Market (2024-2032): North America, leading in terms of revenue 1.26 USD Billion in 2024
- Key Country: U.S., leading in terms of revenue with value of 893.57 USD Million in 2024.
Segments and Scope
-
North America Acute Myeloid Leukemia Diagnostics Market to 2032, By Product
- Instruments is the largest segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 879.60 USD Billion in the year 2024.
- Instruments is the Fastest growing segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 17.61 % in forecast period 2025-2032.
-
North America Acute Myeloid Leukemia Diagnostics Market to 2032, By Test
- Blood Test is the largest segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 399.91 USD Billion in the year 2024.
- Blood Test is the Fastest growing segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 21.07 % in forecast period 2025-2032.
-
North America Acute Myeloid Leukemia Diagnostics Market to 2032, By Gender
- Male is the largest segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 732.52 USD Billion in the year 2024.
- Male is the Fastest growing segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 18.64 % in forecast period 2025-2032.
-
North America Acute Myeloid Leukemia Diagnostics Market to 2032, By End User
- Hospitals is the largest segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 441.33 USD Billion in the year 2024.
- Hospitals is the Fastest growing segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 21.12 % in forecast period 2025-2032.
-
North America Acute Myeloid Leukemia Diagnostics Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 861.39 USD Billion in the year 2024.
- Direct Tender is the Fastest growing segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 18.51 % in forecast period 2025-2032.
-
North America Acute Myeloid Leukemia Diagnostics Market to 2032, By Age Group
- 65 and Above is the largest segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 963.88 USD Billion in the year 2024.
- 65 and Above is the Fastest growing segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 17.54 % in forecast period 2025-2032.
-
North America Acute Myeloid Leukemia Diagnostics Market to 2032, By Cancer
- Myeloblastic (M0) is the largest segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 363.44 USD Billion in the year 2024.
- Myeloblastic (M0) is the Fastest growing segment in North America Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 23.49 % in forecast period 2025-2032.
North America Acute Myeloid Leukemia Diagnostics Market Company Share Analysis
| Company Name |
|
||
| Myriad Genetics, Inc. | |||
| Sysmex Corporation | |||
| QIAGEN | |||
| BIOMÉRIEUX | |||
| CANON MEDICAL SYSTEMS CORPORATION | |||
North America Acute Myeloid Leukemia Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Billion
North America Acute Myeloid Leukemia Diagnostics Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The North America Acute Myeloid Leukemia Diagnostics Market is segmented based on Segmentation Product,Test,Gender,End User,Distribution Channel,Age Group,Cancer.
North America Acute Myeloid Leukemia Diagnostics Market was valued at USD 1.26(Revenue in USD Billion) in 2021.
North America Acute Myeloid Leukemia Diagnostics Market is projected to grow at a CAGR of 16.70% during the forecast period of 2024 to 2032.
The 65 and Above segment is expected to dominate the North America Acute Myeloid Leukemia Diagnostics Market, holding a largest market share of 0.96 USD Billion in 2024
North America Acute Myeloid Leukemia Diagnostics Market Scope
North America Acute Myeloid Leukemia Diagnostics Market Segmentation & Scope
Product
- Consumables & Accessories
- Instruments
Test
- Others
- Immunophenotyping
- Biomarker Test
- Genetic Tests
- Bone Marrow Tests
- Imaging Test
- Blood Test
Gender
- Female
- Male
End User
- Others
- Cancer Research Institutes
- Diagnostic Imaging Centers
- Independent Diagnostic Laboratories
- Associated Labs
- Hospitals
Distribution Channel
- Retail Sales
- Direct Tender
Age Group
- 21-29
- Below 21
- 30-65
- 65 and Above
Cancer
- Megakaryocytic (M7)
- Erythroleukemia (M6)
- Monocytic (M5)
- Myelomonocytic (M4)
- Promyelocytic (M3)
- Myeloblastic (M2)
- Myeloblastic (M1)
- Myeloblastic (M0)
Frequently Asked Questions
The North America Acute Myeloid Leukemia Diagnostics Market is segmented based on Segmentation Product,Test,Gender,End User,Distribution Channel,Age Group,Cancer.
North America Acute Myeloid Leukemia Diagnostics Market was valued at USD 1.26(Revenue in USD Billion) in 2021.
North America Acute Myeloid Leukemia Diagnostics Market is projected to grow at a CAGR of 16.70% during the forecast period of 2024 to 2032.
The estimated market value of the North America Acute Myeloid Leukemia Diagnostics Market for final year is USD 2.98 (USD Billion).
North America Acute Myeloid Leukemia Diagnostics Market Company Profiling
Frequently Asked Questions
The North America Acute Myeloid Leukemia Diagnostics Market is segmented based on Segmentation Product,Test,Gender,End User,Distribution Channel,Age Group,Cancer.
North America Acute Myeloid Leukemia Diagnostics Market was valued at USD 1.26(Revenue in USD Billion) in 2021.
North America Acute Myeloid Leukemia Diagnostics Market is projected to grow at a CAGR of 16.70% during the forecast period of 2024 to 2032.
The estimated market value of the North America Acute Myeloid Leukemia Diagnostics Market for final year is USD 2.98 (USD Billion).
CHOOSE LICENCE TYPE
- 4200.00
- 3500.00
- 2000.00
- 5500.00
- 8500.00
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.